JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is 1.30 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,135,000 | +37.6% | 67,600 | -31.9% | 0.05% | +43.8% |
| Q3 2017 | $825,000 | +59.9% | 99,300 | -17.7% | 0.03% | +68.4% |
| Q2 2017 | $516,000 | +5.7% | 120,700 | +5.5% | 0.02% | -5.0% |
| Q1 2017 | $488,000 | -38.5% | 114,358 | -31.5% | 0.02% | -31.0% |
| Q4 2016 | $793,000 | +10.1% | 167,058 | -6.9% | 0.03% | -9.4% |
| Q3 2016 | $720,000 | -52.9% | 179,362 | +36.4% | 0.03% | -58.4% |
| Q2 2016 | $1,528,000 | +34.3% | 131,458 | +41.0% | 0.08% | +2.7% |
| Q1 2016 | $1,138,000 | +31.1% | 93,239 | +10.3% | 0.08% | +56.2% |
| Q4 2015 | $868,000 | – | 84,500 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |